Royal Bank of Canada
LABD icon

Royal Bank of Canada’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Royal Bank of Canada’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-33
Closed -$170K – 6830
2018
Q2 		$170K Buy
+33
New +$200K ﹤0.01% 4504

Other funds holding LABD

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Royal Bank of Canada's LABD Position: Q3 2018 in Review

Royal Bank of Canada sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q3 2018, closing a stake of 33 shares — an estimated $170K sold.

Royal Bank of Canada first reported a position in LABD in Q2 2018 and held it in 1 quarter. The position peaked at $170K in Q2 2018. 11 funds tracked by Wall St. Rank hold LABD as of Q3 2018.

  • Royal Bank of Canada reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q3 2018 after selling out during the quarter.
  • Royal Bank of Canada sold 33 Direxion Daily S&P Biotech Bear 3X ETF shares in Q3 2018, an estimated $170K.
  • Royal Bank of Canada first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q2 2018 and held it in 1 quarter.
  • Royal Bank of Canada's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $170K in Q2 2018.
  • 11 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q3 2018.

Based on Royal Bank of Canada's 13F filing for Q3 2018, filed 14 Nov 2018.